comparemela.com

Latest Breaking News On - பூமி பரிசோதனை - Page 1 : comparemela.com

Blue Earth Diagnostics Supports Timely Consideration and Passage of the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by U S Congress

Blue Earth Diagnostics Supports Timely Consideration and Passage of the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by U S Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Blue Earth Diagnostics Announces Axumin (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today highlighted presentations at the 2021 American Society

Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years May 25, 2021   Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose treatment integrated Axumin PE

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.